Core Viewpoint - The strategic collaboration between Innovent Biologics and Eli Lilly aims to advance global research and development of innovative drugs in oncology and immunology, marking the seventh partnership between the two companies [1][2] Group 1: Partnership Details - The collaboration involves Innovent Biologics and its subsidiaries, including Fortvita Biologics, and Eli Lilly, focusing on the global development of innovative drugs [1] - Innovent will lead the projects from drug discovery to clinical concept verification in China, while Eli Lilly will have exclusive development and commercialization rights outside Greater China [1] Group 2: Financial Aspects - Innovent will receive an upfront payment of $350 million, with potential milestone payments totaling up to approximately $8.5 billion based on specific future achievements [2] - The company will also earn a tiered sales share from net sales of each product outside Greater China [2] Group 3: Innovation Ecosystem - This partnership breaks traditional licensing models, creating a seamless end-to-end innovation ecosystem that integrates Innovent's drug discovery and early development capabilities with Eli Lilly's extensive global presence [2] - The collaboration reinforces Innovent's core R&D capabilities and aims to accelerate the translation of scientific discoveries into impactful medical solutions for global patients [2]
信达生物(01801)与礼来制药达成全球战略合作推进肿瘤及免疫领域的新药开发